FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
2010 · Annals of Oncology · 181 citations
https://doi.org/10.1093/annonc/mdq585
K
K. Aogi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
67
Papers
1.1K
Citations
15
h-index
18
i10-index
K. Aogi is an academic researcher from Shikoku Cancer Center. The author has contributed to research in topics: Cancer Treatment and Pharmacology & Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research. The author has an h-index of 15, co-authored 57 publications.
Papers by this author
worksChanges in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry
2015 · Annals of Oncology · 181 citations
https://doi.org/10.1093/annonc/mdv611
Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer
2014 · Japanese Journal of Clinical Oncology · 24 citations
https://doi.org/10.1093/jjco/hyu160
A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)
2024 · Annals of Oncology · 16 citations
https://doi.org/10.1016/j.annonc.2024.09.001
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat